Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

This study is testing a combination of three treatments — cabozantinib (a targeted therapy), ipilimumab and nivolumab (two immunotherapy drugs), and TACE (a procedure that delivers chemotherapy directly into tumors in the liver) — in patients with hepatocellular carcinoma (liver cancer) who are not candidates for surgery or transplant. **You may be eligible if:** - You have liver cancer confirmed by biopsy or imaging - You have at least one tumor that can be treated with TACE (a procedure delivering chemo directly to the liver) - Your liver function is relatively preserved (Child-Pugh A or B7) - You are 18 or older with a good performance status (ECOG 0-2) - You have at least one measurable tumor - Your blood counts and organ function meet required levels - You are willing to use contraception if of childbearing potential **You may NOT be eligible if:** - You have had a prior liver transplant - You have uncontrolled infections - You are pregnant or breastfeeding - You have serious autoimmune disease - Your liver disease is severe (Child-Pugh C) - You have significant heart, kidney, or other organ failure Talk to your doctor to see if this trial is right for you.